Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Rolls-Royce's Pearl 10X engine series
Investing Articles

Can the Rolls-Royce share price do it again in 2026?

Can the Rolls-Royce share price do it again? The FTSE 100 company has been a star performer in recent years…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

After huge gains for S&P 500 tech stocks in 2025, here are 4 moves I’m making to protect my ISA and SIPP

Gains from S&P tech stocks have boosted Edward Sheldon’s retirement accounts this year. Here’s what he’s doing now to reduce…

Read more »

View of Lake District. English countryside with fields in the foreground and a lake and hills behind.
Investing Articles

With a 3.2% yield, has the FTSE 100 become a wasteland for passive income investors?

With dividend yields where they are at the moment, should passive income investors take a look at the bond market…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Should I add this dynamic FTSE 250 newcomer to my Stocks and Shares ISA?

At first sight, a UK bank that’s joining the FTSE 250 isn’t anything to get excited by. But beneath the…

Read more »

Investing Articles

£10,000 invested in BT shares 3 months ago is now worth

BT shares have been volatile lately and Harvey Jones is wondering whether now is a good time to buy the…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After a 66% fall, this under-the-radar growth stock looks like brilliant value to me

Undervalued growth stocks can be outstanding investments. And Stephen Wright thinks he has one in a company analysts seem to…

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Don’t ‘save’ for retirement! Invest in dirt cheap UK shares to aim for a better lifestyle

Investing in high-quality and undervalued UK shares could deliver far better results when building wealth for retirement. Here's how.

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1 growth and 1 income stock to kickstart a passive income stream

Diversification is key to achieving sustainable passive income. Mark Hartley details two broadly different stocks for beginners.

Read more »